Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center.

GVHD severity eGVHD App

Journal

Blood cell therapy
ISSN: 2432-7026
Titre abrégé: Blood Cell Ther
Pays: Japan
ID NLM: 9918333884906676

Informations de publication

Date de publication:
25 Feb 2023
Historique:
received: 21 10 2022
accepted: 12 12 2022
medline: 16 6 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

Assessing acute and chronic graft-versus-host disease (GVHD) is challenging because there are several classification systems. The European Society for Blood and Marrow Transplantation and the Center for International Bone Marrow Transplantation Registry task force recommends using the eGVHD application (App) to score acute GVHD according to the Mount Sinai Acute GvHD International Consortium (MAGIC) criteria and chronic GVHD according to the National Institutes of Health 2014 criteria. We prospectively used the eGVHD App at each follow-up visit in a large-volume bone-marrow transplant center in India from 2017 to 2021. We retrospectively evaluated the discrepancy in scoring GVHD severity by physicians not using the App from the same patient charts. The App user satisfaction and experience were recorded using the technology acceptance model (TAM) and the Post-Study System Usability Questionnaire (PSSUQ). In 100 consecutive allogeneic hematopoietic cell transplantation recipients, there was more discrepancy in scoring the severity of chronic GVHD (38%) than acute GVHD (9%) without using the App. The median TAM and PSSUQ scores were six (IQR:1) and two (IQR:1), respectively, indicating high perceived usefulness and user satisfaction. The eGVHD App is an excellent learning tool for hematology/BMT fellows and helps manage GVHD in high-volume BMT centers.

Identifiants

pubmed: 37324565
doi: 10.31547/bct-2022-017
pmc: PMC10266919
doi:

Types de publication

Journal Article

Langues

eng

Pagination

18-22

Informations de copyright

Copyright Ⓒ2023 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website.

Références

Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Haematologica. 2018 Oct;103(10):1698-1707
pubmed: 29903762
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Bone Marrow Transplant. 2016 Aug;51(8):1062-5
pubmed: 27042834
Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10
pubmed: 26386318
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Br J Haematol. 1997 Jun;97(4):855-64
pubmed: 9217189

Auteurs

Prashant Chhabra (P)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Kripa Shanker Kasudhan (KS)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Niranjan Khaire (N)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Shaweta Kaundal (S)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Madhu Chopra (M)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Charanpreet Singh (C)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Aditya Jandial (A)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Arihant Jain (A)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Gaurav Prakash (G)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Alka Khadwal (A)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Pankaj Malhotra (P)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Deepesh P Lad (DP)

Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Classifications MeSH